WO2014152513A1 - RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS - Google Patents

RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS Download PDF

Info

Publication number
WO2014152513A1
WO2014152513A1 PCT/US2014/027422 US2014027422W WO2014152513A1 WO 2014152513 A1 WO2014152513 A1 WO 2014152513A1 US 2014027422 W US2014027422 W US 2014027422W WO 2014152513 A1 WO2014152513 A1 WO 2014152513A1
Authority
WO
WIPO (PCT)
Prior art keywords
mrna
thio
mrna molecule
page
residues
Prior art date
Application number
PCT/US2014/027422
Other languages
English (en)
French (fr)
Inventor
Frank Derosa
Michael Heartlein
Original Assignee
Shire Human Genetic Therapies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2014239562A priority Critical patent/AU2014239562B2/en
Priority to JP2016502430A priority patent/JP6567494B2/ja
Application filed by Shire Human Genetic Therapies, Inc. filed Critical Shire Human Genetic Therapies, Inc.
Priority to CN201480010106.8A priority patent/CN105026411A/zh
Priority to EP14721635.2A priority patent/EP2970351B1/en
Priority to ES14721635.2T priority patent/ES2647832T3/es
Priority to BR112015022507A priority patent/BR112015022507A2/pt
Priority to SG11201507474QA priority patent/SG11201507474QA/en
Priority to EP20169380.1A priority patent/EP3750903A1/en
Priority to EA201591281A priority patent/EA201591281A1/ru
Priority to US14/776,506 priority patent/US10266559B2/en
Priority to MX2015011943A priority patent/MX2015011943A/es
Priority to CA2902884A priority patent/CA2902884C/en
Priority to EP17189627.7A priority patent/EP3301102B1/en
Priority to KR1020157021965A priority patent/KR20150127582A/ko
Publication of WO2014152513A1 publication Critical patent/WO2014152513A1/en
Priority to IL240465A priority patent/IL240465A0/he
Priority to ZA2015/07605A priority patent/ZA201507605B/en
Priority to HK16107939.1A priority patent/HK1219955A1/zh
Priority to AU2018203985A priority patent/AU2018203985B2/en
Priority to US16/282,106 priority patent/US10822368B2/en
Priority to US17/032,485 priority patent/US11447520B2/en
Priority to US17/818,858 priority patent/US20230192753A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Definitions

  • the present invention relates to messenger ribonucleic acids (mRNAs) comprising 4'-thio-modified nucleotide residues, compositions comprising those mRNAs, and methods of making and using same.
  • mRNAs messenger ribonucleic acids
  • mRNA messenger RNA
  • mRNA for in vivo protein production typically required mRNA being packaged (such as, e.g., mRNA complexed with a polymer or lipid carrier). See, e.g., International Patent Appl. Publ. Nos. WO 2011/06810 and WO 2012/170930.
  • the mRNA may undergo degradation, for example upon exposure to one or more nucleases in vivo.
  • Ribonucleases represent a class of nuclease enzymes that are capable of catalyzing the degradation of RNA into smaller components and thereby render the mRNA unable to produce the therapeutic protein.
  • Nuclease enzymes e.g., RNase
  • RNase a nuclease enzyme capable of shortening the circulatory half-life of, for example, synthetically or recombinantly-prepared mRNAs. Following nucleo lytic degradation, an mRNA is not translated, and thus, is prevented from exerting an intended therapeutic benefit, which can significantly reduce the efficacy of the mRNA gene therapy.
  • the present invention provides an improved modified mRNA for more stable, robust and sustained in vivo protein production.
  • the present invention is based, in part, on the realization that the stability of mRNA used to produce therapeutic proteins in vivo can be further improved by incorporating modified ribonucleotides in which the 4' oxygen in the ribose moiety is substituted by a sulfur. Although substitution of the 4' oxygen in the ribose moiety of ribonucleotides with a sulfur has been reported previously by S. Hoshika et al. (Nuc. Ac. Res. Supp. 3:209-210 (2003)) and M. Takahashi, M. et al. (Nuc. Ac. Res.
  • 6078040vl Attorney Docket No.: 2006685-0457 the effect of incorporating 4'-thioribonucleotides into a full length mRNA (that is, an mRNA encoding a full length functional therapeutic protein and optionally containing one or more noncoding regions), which generally has a length much longer than any of the interfering RNAs or aptamers tested in the prior art and does not exist in a uniformly duplexed state and may adopt a conformation with a large non-helical and/or single-stranded component. More importantly, it was unclear if mRNAs incorporating 4'-thio-modified nucleotides could be successfully used for in vivo protein production prior to the present invention.
  • the present inventors have successfully synthesized full length mRNAs incorporating one or more 4'-thio-modified nucleotides (e.g., 4'-thio-ATPs, 4'-thio-UTPs, 4'-thio-GTPs, and/or 4'-thio-CTPs).
  • 4'-thio-ATPs e.g., 4'-thio-ATPs, 4'-thio-UTPs, 4'-thio-GTPs, and/or 4'-thio-CTPs.
  • 4'-thio-modified nucleotides e.g., 4'-thio-ATPs, 4'-thio-UTPs, 4'-thio-GTPs, and/or 4'-thio-CTPs.
  • 4'-thio-ATPs e.g., 4'-thio-ATPs, 4'-thio-UTPs, 4'-thio-GTPs, and/or 4'-thi
  • the present invention provides mRNAs that allow better control over, for example, the stability, immunogenicity, and translational efficiency of the mRNA, and compositions comprising those mRNAs and, optionally, a carrier, as well as methods of using those mRNAs and compositions to induce expression of a therapeutic protein in vivo for treatment of diseases and/or disorders.
  • the invention provides an mRNA molecule having a coding region and optionally, one or more non-coding regions, wherein the mRNA comprises at least one nucleotide residue that incorporates a 4'-thio-substituted furanose ring.
  • a provided mRNA contains at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% nucleotide residues that incorporate a 4'-thio-substituted furanose ring.
  • a provided mRNA contains 100%) nucleotide residues that incorporate a 4'-thio-substituted furanose ring. In some embodiments, a provided mRNA contains up to 5%, 10%>, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%), 98%o, 99%) or 100% 4'-thio-ATPs. In some embodiments, a provided mRNA contains up
  • 6078040vl Attorney Docket No.: 2006685-0457 to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% 4'-thio-UTPs.
  • a provided mRNA contains up to 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% 4'-thio-GTPs.
  • a provided mRNA contains up to 5%, 10%>, 15%, 20%>, 25%, 30%>, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% 4'-thio-CTPs.
  • a provided mRNA contains a combination of various 4'-thio-modified NTPs described herein.
  • a provided mRNA comprises a non-coding region.
  • a provided mRNA comprises a poly-A and/or a poly-U tail.
  • a provided mRNA comprises a 5' cap structure.
  • a provided mRNA further comprises at least one nonstandard nucleotide residue.
  • the at least one nonstandard nucleotide residue is chosen from one or more of 5-methyl-cytidine, pseudouridine, and 2-thio-uridine.
  • the at least one nonstandard nucleotide residue incorporates a 4'-thio- furanose ring.
  • nonstandard nucleotide residues incorporate a 4'-thio-furanose ring.
  • a provided mRNA is at least 60 residues in length. In some embodiments, a provided mRNA is at least about 70, about 80, about 90, about 100, about 150, about 200, about 300, about 400, about 500, about 1,000, about 1,500, about 2,000, about 2,500, about 3,000, about 3,500, about 4,000, about 4,500, or about 5,000 residues in length.
  • compositions comprising at least one mRNA molecule having a coding region and optionally, one or more non-coding regions, wherein the mRNA comprises at least one nucleotide residue that incorporates a 4'-thio- substituted furanose ring and a carrier.
  • a provided composition comprises at least one mRNA having a coding region and optionally, one or more non-coding regions, wherein the mRNA comprises at least one nucleotide residue that incorporates a 4'-thio- substituted furanose ring and a carrier, and the mRNA is at least 60 residues in length.
  • compositions of the invention comprise at least one mRNA molecule having a coding region and optionally, one or more non-coding regions, wherein the mRNA comprises at least one nucleotide residue that incorporates a 4'-thio-substituted furanose ring, and is complexed with a polymer based carrier or a lipid nanoparticle.
  • the invention further provides methods of producing a therapeutic protein in vivo, comprising administering to a subject at least one mRNA molecule having a coding region and optionally, one or more non-coding regions, wherein the mRNA comprises at least one nucleotide residue that incorporates a 4'-thio-substituted furanose ring, or a composition comprising such mRNA and a carrier.
  • the invention also provides methods of treating a subject in need of a therapeutic protein, comprising administering at least one mRNA molecule having a coding region and optionally, a non-coding region, wherein the mRNA comprises at least one nucleotide residue that incorporates a 4'-thio-substituted furanose ring, or a composition comprising such mRNA and a carrier.
  • an administered mRNA in a provided method is at least 60 residues in length.
  • Various modified mRNAs described herein may be used for production of therapeutic proteins or for treatment of various diseases, disorders or conditions.
  • the present invention provides a method for producing a protein using a modified mRNA described herein. Such a method of protein production may be used in an in vitro cell free system, in vitro cell based system, or in vivo system.
  • a suitable mRNA comprises at least one nucleotide residue that incorporates a 4'- thio-substituted furanose ring.
  • a suitable mRNA comprises up to about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of nucleotide residues (e.g., ATP, CTP, GTP, UTP, and/or non-standard NTPs) that incorporate a 4'-thio-substituted furanose ring.
  • a provided mRNA comprises a poly(A) or poly(U) tail.
  • a provided mRNA is at least 60 residues in length.
  • the present invention provides use of a provided mRNA molecule for the manufacture of a medicament that is capable of producing a therapeutic protein in vivo.
  • the present invention provides a method for making a provided mRNA. In some other embodiments, the present invention provides a method for in vitro synthesis of a provided mRNA. In some other embodiments, the present invention provides a method for making (e.g., in vitro synthesizing) a provided mRNA containing up to about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% of nucleotide residues (e.g., ATP, CTP, GTP, UTP, and/or non-standard NTPs) that incorporate a 4'-thio-substituted furanose ring.
  • nucleotide residues e.g., ATP, CTP, GTP, UTP, and/or non-standard NTPs
  • the present invention provides a method for making (e.g., in vitro synthesizing) a provided mRNA at least about 60, about 70, about 80, about 90, about 100, about 150, about 200, about 300, about 400, about 500, about 1,000, about 1,500, about 2,000, about 2,500, about 3,000, about 3,500, about 4,000, about 4,500, or about 5,000 residues in length.
  • Figure 1 shows molecular structures of exemplary 4'-thioRNA bases: 4'-thio- adenosine, 4'-thio-guanosine, 4'-thio-cytidine, 4'-thio-uridine, 4'-thio-5-methyl-cytidine, 4'-thio- pseudouridine, and 4'-thio-2-thiouridine.
  • Figure 2 shows luciferase detection from FFL luciferase production in HEK 293T cells post-transfection of modified and unmodified FFL mRNA.
  • Figure 3 shows the results of a stability study of modified and unmodified FFL mRNA.
  • Figure 4 shows luciferase detection from FFL luciferase production in mouse liver post-administration of modified and unmodified FFL mRNA.
  • mRNA is used to refer to modified and/or unmodified
  • RNA including a coding region and, optionally, a noncoding region.
  • coding region refers to a portion or region of the mRNA that can be translated into a chain of amino acids, i.e., two or more amino acids linked by peptide bonds. A chain of amino acids is also referred to as a peptide or a polypeptide, which can fold into a protein (e.g., a therapeutic protein).
  • noncoding region refers to a portion or region of the mRNA that are typically not translated. Noncoding region typically includes 5' untranslated region and/or 3' untranslated region including but not limited to a poly(A) or poly(U) tail.
  • a "nonstandard nucleobase” is a base moiety other than the natural bases adenine
  • the nonstandard nucleobase is an analog of a specific nucleobase (A, C, G, T, or U) when its base pairing properties in a nucleic acid double helix and locus of incorporation by DNA or RNA polymerases in a nucleic acid double helix (including a local RNA-DNA helix such as that formed during transcription of a DNA template by RNA polymerase) are most similar to one of the five previously listed nucleobases, with the exception that analogs of T will generally also be analogs of U and vice versa.
  • nonstandard used in conjunction with terms including but not limited to "nucleoside,” “base,” “nucleotide,” or “residue” is to be interpreted in the same manner as if it were used in conjunction with "nucleobase.”
  • therapeutic protein includes any protein that, if administered to a subject, provides a beneficial effect on the health and well-being of the subject.
  • a deficiency, lack of, or aberrant expression of that protein in a subject gives rise to a disease or condition.
  • “Therapeutic protein” may also refer to a protein that is not normally present or is not normally present in sufficient quantities in a subject to achieve a desired therapeutic effect.
  • helper lipid refers to any neutral or zwitterionic lipid material including cholesterol. Without wishing to be held to a particular theory, helper lipids may add stability, rigidity, and/or fluidity within lipid bilayers/nanoparticles.
  • the mRNAs of the invention employ specific chemically-modified bases, in which the 4' oxygen in the ribose moiety of a nucleotide residue is replaced with sulfur, for substitution into a messenger ribonucleic acid molecule to enhance its biological properties upon administration to a subject.
  • Exemplary 4'-thio modified nucleotide residues for incorporation into an mRNA of the invention are depicted in Figure 1 (showing modified nucleotide residues containing a thio-substituted furanose ring).
  • 4'-thio modification of the furanose ring provides improved resistance to exonucleases, endonucleases, and/or other RNA degradation enzymes in human serum.
  • RNA half-life can afford an increased RNA half-life.
  • administration of an mRNA having a 4'-thio modification in the furanose ring or a composition comprising such mRNA results in cellular uptake of an mRNA having improved biological properties, e.g., increased half-life, which in turn contributes to increased protein production in vivo.
  • RNA have a 4'-thio modification in the furanose ring.
  • about 1-5%, 5-15%, 15- 30%, 30-50%, 50-75%, 75-90%, 90-99%, or 99-100% of the adenosine in the mRNA can be 4'- thio-adenosine.
  • adenosine residues in the mRNA are 4'-thio- adenosine.
  • about 100% of the adenosine residues in the mRNA are 4'- thio-adenosine.
  • RNA have a 4'-thio modification in the furanose ring.
  • about 1-5%, 5-15%, 15- 30%, 30-50%, 50-75%, 75-90%, 90-99%, or 99- 100% of the guanosine in the mRNA can be 4'- thio-guanosine.
  • guanosine residues in the mRNA are 4'-thio- guanosine.
  • about 100% of the guanosine residues in the mRNA are 4'- thio-guanosine.
  • At least 1 % of the uridine nucleotide residues in the RNA have a 4'-thio modification in the furanose ring.
  • about 1-5%, 5-15%, 15-30%), 30- 50%, 50-75%, 75-90%, 90-99%, or 99-100% of the uridine in the mRNA can be 4'-thio-uridine.
  • uridine residues in the mRNA are 4'-thio- uridine.
  • about 100%) of the uridine residues in the mRNA are 4'-thio- uridine.
  • RNA have a 4'-thio modification in the furanose ring.
  • about 1 -5%, 5-15%, 15- 30%, 30-50%, 50-75%, 75-90%, 90-99%, or 99-100% of the cytidine in the mRNA can be 4'- thio-cytidine.
  • cytidine residues in the mRNA are 4'-thio- cytidine.
  • about 100%) of the cytidine residues in the mRNA are 4'-thio- cytidine.
  • each 4'-thio-modified nucleotide in a provided mRNA is
  • each 4'-thio-modified nucleotide in a provided mRNA is 4'-thio-cytidine. In some embodiments, each 4'-thio-modified nucleotide in a provided mRNA is independently 4'-thio-uridine or 4'-thio-cytidine. In some embodiments, a provided mRNA comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more 4'-thio-uridine or 4'-thio-cytidine. In some embodiments, a provided mRNA comprises at least one 4'-thio-adenosine residue.
  • a provided mRNA comprises at least one 4'-thio-guanosine residue. In some embodiments, a provided mRNA comprises at least one 4'-thio-guanosine or 4'-thio-adenosine residue. In some embodiments, a provided mRNA comprises at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more 4'-thio-guanosine or 4'-thio-adenosine residues.
  • the fraction of nucleotide residues with a 4'-thio modification in the furanose ring of one base type varies independently of the fraction of modified nucleotide residues of the other base types.
  • less than 10% of the nucleotide residues have a 4'-thio modification in the furanose ring.
  • a 4'-thio modification in the furanose ring For example, about 1-5%, 5-10%, 3-5%, 1-3%, 0.1-1%, or 0.01-O.
  • P/o of the nucleotide residues can incorporate a 4'-thio-substituted furanose ring.
  • more than 10% of the nucleotide residues have a 4'-thio modification in the furanose ring. For example, about 10-15%), 15-20%), 20-25%), 25-30%), 30- 35%), 35-40%), 40-45%) or 45-50%) of the nucleotide residues can incorporate a 4'-thio-substituted furanose ring. In some embodiments, more than 50% of the nucleotide residues have a 4'- thioRNA modification in the furanose ring.
  • nucleotide residues incorporate a 4'-thio-substituted furanose ring.
  • nucleotide residues can incorporate a 4'-thio-substituted furanose ring.
  • nucleotide residues can incorporate a 4'-thio-substituted furanose ring.
  • the coding and non-coding regions in the mRNAs of the invention may encompass non-contiguous regions of sequence.
  • the optional non-coding regions may include one or more of a 5' untranslated region (UTR), a 3' UTR, a poly-A, poly-U or poly-C tail, and/or a 5' cap structure.
  • a provided mRNA comprises a non-coding region.
  • a provided mRNA comprises a 5' UTR.
  • a provided mRNA comprises a 3 ' UTR.
  • a provided mRNA comprises a 5 ' cap structure.
  • a provided mRNA comprises a poly-A tail.
  • a provided mRNA comprises a 5'-UTR sequence, a 3'-UTR sequence and a poly- A tail. In some embodiments, a provided mRNA comprises a 5' -UTR sequence, a coding region, a 3' -UTR sequence and a poly-A tail. In some embodiments, a provided mRNA comprises a 5'-UTR sequence, a 5' cap, a 3'-UTR sequence and a poly-A tail. In some embodiments, a provided mRNA comprises a 5'-UTR sequence, a 5' cap, a coding region, a 3'- UTR sequence and a poly-A tail.
  • the poly-A, poly-U or poly-C tail comprises nucleotide residues that incorporate a 4'-thio-substituted furanose ring.
  • only the poly-A, poly-U or poly-C tail or other components of the non-coding region incorporate nucleotide residues having a 4'-thio substitution in the furanose ring, while the remainder of the nucleotide residues in the mRNA molecule do not contain a 4'-thio-furanose modification.
  • the coding region comprises nucleotide residues that incorporate a 4'-thio- substituted furanose ring.
  • both the coding and non-coding regions incorporate nucleotide residues having a 4'-thio substitution in the furanose ring.
  • the length of the poly-A, poly-U or poly-C tail may vary.
  • the length of the poly-A, poly-U, or poly-C tail may be at least about 50, 70, 90, 100, 150, 200, 250, 300, 400, or 500 nucleotides in length.
  • the length of the poly-A, poly-U or poly-C tail is less than about 90, 100, 150, 200, 250, 300, 400, or 500 nucleotides in length.
  • the mRNA molecule may include modifications in addition to a 4'-thio- substituted furanose ring.
  • the molecule may incorporate any nonstandard nucleobase.
  • Certain embodiments may include nucleotide residue modifications such as 5-
  • 6078040vl Attorney Docket No. : 2006685-0457 methyl-cytidine ("5mC"), pseudouridine (“ ⁇
  • a 4'-thio substituted furanose ring can be included within an unmodified or a modified base such as, e.g., pseudouridine, 2-thiouridine, and 5-methylcytidine.
  • any of these modifications may be present in 0-100% of the nucleotide residues— for example, more than 0%, 1%, 10%, 50%, 90% or 95%, or 100% of the nucleotide residues individually or in combination.
  • a provided mRNA comprises at least one nonstandard nucleotide residue.
  • the at least one nonstandard nucleotide residue is chosen from one or more of 5 -methyl-cytidine,
  • the at least one nonstandard nucleotide residue in 5 -methyl-cytidine. In some embodiments, the at least one nonstandard nucleotide residue incorporates a 4'-thio-furanose ring. In some embodiments, up to 5%, 10%>, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% nonstandard nucleotide residues incorporate a 4'-thio- furanose ring.
  • Additional modifications may include, for example, sugar modifications or substitutions (e.g., one or more of a 2'-0-alkyl modification, a locked nucleic acid (LNA)).
  • sugar modifications or substitutions e.g., one or more of a 2'-0-alkyl modification, a locked nucleic acid (LNA)
  • LNA locked nucleic acid
  • such modification may include, but are not limited to a 2'-deoxy-2'-fluoro modification, a 2'-0-methyl modification, a 2'-0-methoxyethyl modification and a 2'-deoxy modification.
  • 0-100% of the mRNA may be single-stranded. In certain embodiments, 0-100% of the RNA may adopt a non-helical conformation.
  • compositions of the invention comprise mRNAs in which about 100% of the uridine residues are replaced with 4'-thio-uridine.
  • compositions of the invention comprise mRNAs in which about 100% of the uridine residues are replaced with 4'-thio-uridine and about 100% of the cytidine residues are replaced with 5-methyl-cytidine.
  • compositions of the invention comprise mRNAs in which about 100% of the uridine residues are replaced with 4'-thio-pseudouridine.
  • compositions of the invention comprise mRNAs in which about 100%) of the uridine residues are replaced with 4'-thio-pseudouridine and about 100%) of the cytidine residues are replaced with 5-methyl-cytidine.
  • a provided mRNA provides a beneficial biological effect, for example but not limited to increased stability, improved protein production rate, and/or higher protein yield, when compared with a corresponding natural mRNA.
  • a provided mRNA has increased stability (e.g., a longer serum half-life) when administered in vivo, as compared with a corresponding natural mRNA (i.e., a corresponding mRNA without modification).
  • the mRNA of the invention can be more resistant to nuclease (e.g., endonuclease) degradation to an extent that results in an increase in the amount of the therapeutic protein translated from the mRNA transcript upon administration to a subject by at least about 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 33%, 36%, 40%, 50%, 60%, 70%, 75%, 80%, 90%, 95%, 99%, 100%, 110%, 120%, 125%, 150%, 175%, 200%, 250%, 300%, 400%, 500%, 600%, 700%, 750%), 800%), 900%), or 1,000%>, as compared to a corresponding mRNA without modification.
  • nuclease e.g., endonuclease
  • the length of the modified mRNA molecule in the compositions of the invention is at least 200 nucleotide residues in length.
  • the mRNA may be at least about 200, 300, 400, 500, 1000, 2000, 3000, 4000, or 5000 nucleotide residues in length.
  • a provided mRNA is at least 60 residues in length.
  • a provided mRNA is at least about 70, about 80, about 90, about 100, about 150, about 200, about 300, about 400, about 500, about 600, about 700, about 800, about 900, about 1,000, about 1,500, about 2,000, about 2,500, about 3,000, about 4,000, about 5,000, about 6,000 or about 7000 residues in length.
  • the therapeutic protein encoded by the mRNAs of the invention may be any protein where a deficiency, lack of, or aberrant expression of that protein gives rise to a disease and/or condition.
  • the therapeutic protein may be an enzyme.
  • the therapeutic protein is one that is not normally present or is not normally present in sufficient quantities in a subject to achieve the desired therapeutic effect.
  • a non-limiting selection of suitable therapeutic proteins includes erythropoietin, insulin, human growth hormone, cystic fibrosis transmembrane conductance regulator (CFTR), insulin, alpha-galactosidase A, alpha-L-iduronidase, iduronate-2-sulfatase, N- acetylglucosamine-1 -phosphate transferase, N-acetylglucosaminidase, alpha-glucosaminide acetyltransferase, N-acetylglucosamine 6-sulfatase, N-acetylgalactosamine-4-sulfatase, beta- glucosidase, galactose-6-sulfate sulfatase, beta-galactosidase, beta-glucuronidase,
  • glucocerebrosidase heparan sulfamidase, hyaluronidase, galactocerebrosidase, ornithine transcarbamylase (OTC), carbamoyl-phosphate synthetase 1 (CPS1), argininosuccinate synthetase (ASS1), argininosuccinate lyase (ASL), arginase 1 (ARG1), glucose-6-phosphatase, glucose-6-phosphate translocase, glycogen debranching enzyme, lysosomal alpha-glucosidase, 1 ,4-alpha-glucan branching enzyme, glycogen phosphorylase, phosphofructokinase, liver phosphorylase, GLUT-2, UDP glycogen synthase, alpha-L-iduronidase, iduronate sulfate silfatase, heparan sulfate sulf
  • porphobilinogen deaminase methylmalonyl-CoA mutase, urate oxidase, CI esterase inhibitor, and acid alpha-glucosidase.
  • the mRNA molecules of the invention may be administered as naked or unpackaged mRNA.
  • the administration of the mRNA in the compositions of the invention may be facilitated by inclusion of a suitable carrier.
  • the carrier is selected based upon its ability to facilitate the transfection of a target cell with one or more mRNAs.
  • carrier includes any of the standard pharmaceutical carriers, vehicles, diluents, excipients and the like which are generally intended for use in connection with the administration of biologically active agents, including mRNA.
  • the compositions and, in particular, the carriers described herein are capable of delivering and/or stabilizing mRNA of varying sizes to their target cells or tissues.
  • compositions of the invention comprise carriers that are capable of delivering large mRNAs (e.g., mRNAs of at least 5kDa, lOkDa, 12kDa, 15kDa, 20kDa, 25kDa, 30kDa, or more, or of at least 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 1,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, 5,000, 5,500, 6,000, 6,500, or 7,000 residues in length).
  • mRNAs according to the present invention may be synthesized according to any of a variety of known methods.
  • mRNAs according to the present invention may be synthesized via in vitro transcription (IVT).
  • IVT is typically performed with a linear or circular DNA template containing a promoter, a pool of ribonucleotide triphosphates including desired amount(s) of 4'-thio-modified standard and/or non-standard ribonucleotides (e.g., one or more desired 4'-thio-NTP(s)) and optionally, mixed with unmodified ribonucleotide triphosphates, a buffer system that may include DTT and magnesium ions, and an appropriate RNA polymerase (e.g., T3, T7 or SP6 RNA polymerase), DNAse I, pyrophosphatase, and/or RNAse inhibitor.
  • RNA polymerase e.g., T3, T7 or SP6 RNA polymerase
  • DNA template is transcribed in vitro.
  • a suitable DNA template typically has a promoter, for example a T3, T7 or SP6 promoter, for in vitro transcription, followed by desired nucleotide sequence for encoding a protein of interest and a termination signal.
  • mRNA synthesis includes the addition of a "cap” on the N-terminal (5') end, and a "tail” on the C- terminal (3') end. The presence of the cap is important in providing resistance to nucleases found in most eukaryotic cells. The presence of a "tail” serves to protect the mRNA from exonuclease degradation.
  • mRNAs according to the present invention include a
  • a 5' cap structure is typically added as follows: first, an RNA terminal phosphatase
  • 6078040vl Attorney Docket No.: 2006685-0457 removes one of the terminal phosphate groups from the 5 ' nucleotide, leaving two terminal phosphates; guanosine triphosphate (GTP) is then added to the terminal phosphates via a guanylyl transferase, producing a 5 '5 '5 triphosphate linkage; and the 7-nitrogen of guanine is then methylated by a methyltransferase.
  • Examples of cap structures include, but are not limited to, m7G(5 * )ppp (5 * (A,G(5 * )ppp(5 * )A and G(5 * )ppp(5 * )G.
  • mRNAs according to the present invention include a 3 ' tail structure.
  • a suitable 3' tail structure includes, but is not limited to, a poly-A, poly-U and/or poly-C tail. Exemplary suitable poly-A, poly-U and poly-C tails are described above. The poly- U or poly-C tail may be added to the poly-A tail or may substitute the poly-A tail.
  • mRNAs according to the present invention include a 5 ' and/or 3' untranslated region.
  • a 5' untranslated region includes one or more elements that affect an mRNA's stability or translation, for example, an iron responsive element.
  • a 5' untranslated region may be between about 50 and 500 nucleotides in length (e.g., about 50 and 400 nucleotides in length, about 50 and 300 nucleotides in length, about 50 and 200 nucleotides in length, or about 50 and 100 nucleotides in length).
  • the carrier may be selected and/or prepared to optimize delivery of the mRNA to a target cell, tissue or organ.
  • the properties of the carrier e.g., size, charge and/or pH
  • the target tissue is the central nervous system (e.g., to facilitate delivery of mRNA polynucleotides to targeted brain region(s) or spinal tissue) selection and preparation of the carrier must consider penetration of, and retention within, the blood brain barrier and/or the use of alternate means of directly delivering such carrier to such target tissue.
  • the compositions of the present invention may be combined with agents that facilitate the transfer of exogenous polynucleotides from the local tissues or organs into which such compositions were administered to one or more peripheral target organs or tissues.
  • the carriers employed in the compositions of the invention may comprise a liposomal vesicle, or other means to facilitate the transfer of an mRNA
  • Suitable carriers include, but are not limited to, polymer based carriers, such as polyethyleneimine (PEI), lipid nanoparticles and liposomes, nanoliposomes, ceramide-containing nanoliposomes, proteoliposomes, both natural and synthetically-derived exosomes, natural, synthetic and semi-synthetic lamellar bodies, nanoparticulates, calcium phosphor-silicate nanoparticulates, sol-gels, calcium phosphate nanoparticulates, silicon dioxide nanoparticulates, nanocrystalline particulates, semiconductor nanoparticulates, poly(D-arginine), nanodendrimers, starch-based delivery systems, micelles, emulsions, niosomes, plasmids, viruses, calcium phosphate nucleotides, aptamers, peptides and other vectorial tags. Also contemplated is the use of bionanocapsules and other viral caps
  • the carrier is formulated using a polymer as a carrier, alone or in combination with other carriers.
  • Suitable polymers may include, for example, polyacrylates, polyalkycyanoacrylates, polylactide, polylactide-polyglycolide copolymers, polycaprolactones, dextran, albumin, gelatin, alginate, collagen, chitosan, cyclodextrins, protamine, PEGylated protamine, PLL, PEGylated PLL and polyethylenimine (PEI), including, but not limited to branched PEI (25 kDa).
  • a polymer may be one or more multi-domain-block polymers.
  • a polymer may comprise a dry powder formulation of the polymer or polymers.
  • liposomal carriers to facilitate the delivery of polynucleotides to target cells is also contemplated by the present invention.
  • Liposomes e.g., liposomal lipid
  • nanoparticles are generally useful in a variety of applications in research, industry, and medicine, particularly for their use as carriers of diagnostic or therapeutic compounds in vivo (Lasic et al., Trends BiotechnoL, 16:307-321 (1998); Drummond et al., Pharmacol. Rev., 51 :691- 743 (1999)) and are usually characterized as microscopic vesicles having an interior aqua space sequestered from an outer medium by a membrane of one or more bilayers.
  • Bilayer membranes of liposomes are typically formed by amphiphilic molecules, such as lipids of synthetic or natural origin that comprise spatially separated hydrophilic and hydrophobic domains. Bilayer membranes of the liposomes can also be formed by amphiphilic polymers and surfactants (e.g., polymerosomes, niosomes, etc.).
  • the mRNA molecules is complexed with lipid nanoparticles to facilitate delivery to the target cell.
  • suitable lipids include, for example, the phosphatidyl compounds (e.g., phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides).
  • the mRNA molecules and compositions of the invention may be combined with a multi-component lipid mixture of varying ratios employing one or more cationic lipids, helper lipids and PEGylated lipids designed to encapsulate various nucleic acid- based materials.
  • Cationic lipids may include, but are not limited to DOTAP (l,2-dioleyl-3- trimethylammonium propane), DODAP (l,2-dioleyl-3-dimethylammonium propane), cKK-E12 (3,6-bis(4-(bis(2-hydroxydodecyl)amino)butyl)piperazine-2,5-dione), dialkylamino-based, imidazole-based, guanidinium-based, XTC (2,2-Dilinoleyl-4-dimethylaminoethyl-[l,3]- dioxolane), MC3 (((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4- (dimethylamino)butanoate), ALNY-100 ((3aR,5s,6aS)-N,N-dimethyl-2,2-di(((3a
  • HGT4003 (WO 2012/170889, the teachings of which are incorporated herein by reference in their entirety), ICE (WO 2011/068810, the teachings of which are incorporated herein by reference in their entirety), HGT5000 (U.S. Provisional Patent Application No. 61/617,468, the teachings of which are incorporated herein by reference in their entirety) or HGT5001(cis or trans) (Provisional Patent Application No.
  • aminoalcohol lipidoids such as those disclosed in WO2010/053572, DOTAP (l,2-dioleyl-3-trimethylammonium propane), DOTMA (l,2-di-0-octadecenyl-3-trimethylammonium propane), DLinDMA (Heyes, et al., J. Contr. Rel. 107:276-287(2005)), DLin-KC2-DMA (Semple, et al, Nature Biotech. 28: 172-176 (2010)), C12-200 (Love, et al, Proc. Nat'l. Acad. Sci. 107: 1864-1869(2010)).
  • a cationic lipid is cK -E12:
  • Suitable helper lipids include, but are not limited to DSPC (1,2-distearoyl-sn- glycero-3-phosphocholine), DPPC (l,2-dipalmitoyl-sn-glycero-3-phosphocholine), DOPE (1,2- dioleyl-sn-glycero-3-phosphoethanolamine), DPPE (1 ,2-dipalmitoyl-sn-glycero-3- phosphoethanolamine), DMPE (l,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DOPG (,2-dioleoyl-sn-glycero-3-phospho-(l'-rac-glycerol)), and cholesterol.
  • DSPC 1,2-distearoyl-sn- glycero-3-phosphocholine
  • DPPC l,2-dipalmitoyl-sn-glycero-3-phosphocholine
  • DOPE 1,2- dioleyl-sn-
  • PEGylated lipids for use in nanoparticle formulations include, but are not limited to a poly(ethylene) glycol chain of up to 5 kDa in length covalently attached to a lipid with alkyl chain(s) of C6-C20 length, DMG-PEG2K, PEG-DSG, PEG-DMG, and PEG-ceramides.
  • the lipid nanoparticle carrier comprises one of the following lipid formulations:
  • the mRNAs of the invention and compositions comprising those mRNAs may be administered in a local rather than systemic manner, for example, via injection of the pharmaceutical composition directly into a targeted tissue, preferably in a sustained release formulation. Local delivery can be affected in various ways, depending on the tissue to be targeted.
  • aerosols containing the mRNAs and compositions of the invention can be inhaled (for nasal, tracheal, or bronchial delivery); mRNAs and compositions of the invention can be injected into the site of injury, disease manifestation, or pain, for example; compositions can be provided in lozenges for oral, tracheal, or esophageal application; can be supplied in liquid, tablet or capsule form for administration to the stomach or intestines, can be supplied in suppository form for rectal or vaginal application; or can even be delivered to the eye by use of creams, drops, or even injection.
  • lyophilized pharmaceutical compositions comprising one or more of the liposomal nanoparticles disclosed herein and related methods for the use of such lyophilized compositions as disclosed for example, in International Patent Publication WO 2012/170889, the teachings of which are incorporated herein by reference in their entirety.
  • lyophilized mRNA and compositions of the invention may be reconstituted prior to administration or can be reconstituted in vivo.
  • a lyophilized mRNA and/or composition can be formulated in an appropriate dosage form (e.g., an intradermal dosage form such as a disk, rod or membrane) and administered such that the dosage form is rehydrated over time in vivo by the individual's bodily fluids.
  • an appropriate dosage form e.g., an intradermal dosage form such as a disk, rod or membrane
  • methods of treating a subject comprising administering an mRNA or composition of the invention are also contemplated.
  • certain embodiments of the invention provide methods of treating or preventing conditions in which production of a particular protein and/or utilization of a particular protein is inadequate or compromised.
  • the present invention provides methods of modulating (e.g., increasing, improving or otherwise enhancing) the translational efficiency of one or more mRNAs in a target cell.
  • translational efficiency refers to the extent to which an mRNA is translated and the encoded therapeutic protein is produced.
  • an mRNA molecule of the invention or composition comprising such mRNA is administered to a patient.
  • an mRNA molecule of the invention or composition comprising such mRNA is used for protein production in an in vitro or in vivo system.
  • a suitable in vitro system my be an in vitro cell free system or an in vitro cell based system.
  • a suitable in vivo system may be any living organism such as a non-human animal (e.g., rat, mouse, pig, dog, chicken, sheep, non-human primate, etc.) or human.
  • EXAMPLE 1 Synthesis and Expression of mRNA Incorporating 4'-thio-substituted furanose ring
  • An mRNA which encodes a protein is synthesized.
  • the mRNA contains at least one 4'-thio-substituted furanose ring.
  • the mRNA is formulated into a pharmaceutical composition and administered to a subject.
  • the mRNA may exhibit a longer half- life and result in a greater amount of synthesis of the protein encoded by the mRNA than a control mRNA which does not contain a 4'-thio-substituted furanose ring.
  • Firefly Luciferase FTL
  • human erythropoietin EPO
  • human alpha- galactosidase GLA
  • FTL Firefly Luciferase
  • EPO human erythropoietin
  • GLA human alpha- galactosidase
  • EPO Human erythropoietin
  • GLA Human alpha-galactosidase
  • FTL Firefly Luciferase
  • Y 2 (3 ' untranslated sequence) (SEQ ID NO:7):
  • Protocol B Aliquots of 50 mg/mL ethanolic solutions of DODAP, DOPE, cholesterol and DMG-PEG2K is mixed and diluted with ethanol to 3 mL final volume.
  • an aqueous buffered solution (10 mM citrate/150 mM NaCl, pH 4.5) of EPO mRNA is prepared from a 1 mg/mL stock.
  • the lipid solution is injected rapidly into the aqueous mRNA solution and shaken to yield a final suspension in 20% ethanol.
  • the resulting nanoparticle suspension was filtered, diafiltrated with lx PBS (pH 7.4), concentrated and stored at 2-8°C.
  • Final concentration 1.35 mg/mL EPO mRNA (encapsulated).
  • 4'-Thio NTP modified messenger RNA are subjected to RNase I or Nuclease PI for various periods of time to allow for sufficient degradation. Upon completion, the resulting monophosphate nucleotides are degraded further with alkaline phosphatase to provide the respective nucleosides.
  • the nucleoside mixture is applied to an Amicon spin column (30,000 MWCO) for efficient enzyme removal. The resulting nucleoside solution is analyzed via HPLC and quantified via peak area comparison with respective unmodified nucleoside.
  • 4'-Thio NTP modified messenger RNA is subjected to RNase I or Nuclease PI for a various periods of time to assess resistance to nuclease degradation.
  • 4'-thio NTP modified messenger RNA was treated with serum (containing nucleases) over various time periods to assess nuclease degradation.
  • the nuclease reactions are quenched with inhibitor and the resulting solution is applied to an Amicon spin column (30,000 MWCO) for efficient enzyme removal.
  • the retentate is applied to a 1% agarose gel and analyzed for mRNA construct viability (size, degradation products, etc).
  • 6078040vl Attorney Docket No.: 2006685-0457 analyzed for EPO and GLA protein, respectively, using ELISA-based methods. A comparison of protein production over time of unmodified versus 4'-thio NTP modified mRNA may be made.
  • unencapsulated (naked) 4'thio NTP modified mRNA and unmodified mRNA are injected via either intravenous, subcutaneous or intratracheal administration and identical analyses may be performed as described above to assess differences of stability and protein production.
  • liver and spleen of each mouse is harvested, apportioned into three parts, and stored in either 10% neutral buffered formalin or snap-frozen and stored at -80°C for analysis.
  • EPO ELISA Quantification of EPO protein is performed following procedures reported for human EPO ELISA kit (Quantikine IVD, R&D Systems, Catalog # Dep-00).
  • Positive controls consist of ultrapure and tissue culture grade recombinant human erythropoietin protein (R&D Systems, Catalog # 286-EP and 287-TC, respectively). Blood samples are taken at designated time points and processed as described above. Detection is monitored via absorption (450 nm) on a Molecular Device Flex Station instrument.
  • GLA ELISA Standard ELISA procedures are followed employing sheep anti-
  • HRP horseradish peroxidase
  • TMB 3,3',5,5'-tetramethylbenzidine
  • Detection is monitored via absorption (450 nm) on a Molecular Device Flex Station instrument. Untreated mouse serum and human REPLAGAL® protein is used as negative and positive controls, respectively.
  • Luciferase Assay The bioluminescence assay is conducted using a Promega
  • the Luciferase Assay Reagent is prepared by adding
  • RLU relative light units
  • This example provides exemplary liposome formulations for effective delivery and expression of 4'-Thio modified mRNA in vivo.
  • the formulations described herein include a multi-component lipid mixture of varying ratios employing one or more cationic lipids, helper lipids (e.g., non-cationic lipids and/or cholesterol-based lipids) and PEGylated lipids designed to encapsulate various nucleic acid-based materials.
  • Cationic lipids can include (but not exclusively) DOTAP (l ,2-dioleyl-3- trimethylammonium propane), DODAP (l ,2-dioleyl-3-dimethylammonium propane) , DOTMA
  • Helper lipids can include (but not exclusively) DSPC (1 ,2- distearoyl-sn-glycero-3-phosphocholine), DPPC (1 ,2-dipalmitoyl-sn-glycero-3-phosphocholine),
  • DOPE (l ,2-dioleyl-sn-glycero-3-phosphoethanolamine), DPPE (l ,2-dipalmitoyl-sn-glycero-3- phosphoethanolamine), DMPE (l ,2-dimyristoyl-sn-glycero-3-phosphoethanolamine), DOPG (,2- dioleoyl-5/7-glycero-3-phospho-(l'-rac-glycerol)), cholesterol, etc.
  • the PEGylated lipids can
  • 6078040vl Attorney Docket No.: 2006685-0457 include (but not exclusively) a poly(ethylene) glycol chain of up to 5 kDa in length covalently attached to a lipid with alkyl chain(s) of C 6 -C2o length.
  • Firefly Luciferase (FFL), human erythropoietin (EPO) and human alpha- galactosidase (GLA) were synthesized by in vitro transcription from a plasmid DNA template encoding the gene, which was followed by the addition of a 5' cap structure (Capl) (Fechter, P.; Brownlee, G.G. "Recognition of mRNA cap structures by viral and cellular proteins" J. Gen. Virology 2005, 86, 1239-1249) and a 3' poly(A) tail of approximately 200 nucleotides in length as determined by gel electrophoresis. 5' and 3' untranslated regions present in each mRNA product are represented as X and Y, respectively and defined as stated (vide infra).
  • EPO erythropoietin
  • GLA human alpha- galactosidase
  • FTL Codon-Optimized Firefly Luciferase
  • DMG-PEG2K were mixed and diluted with ethanol to 3 mL final volume.
  • an aqueous buffered solution (10 mM citrate/150 mM NaCl, pH 4.5) of GLA mRNA was prepared from a 1 mg/mL stock.
  • the lipid solution was injected rapidly into the aqueous mRNA solution and shaken to yield a final suspension in 20% ethanol.
  • the resulting nanoparticle suspension was filtered, diafiltrated with lx PBS (pH 7.4), concentrated, and stored at 2-8°C.
  • DMG-PEG2K were mixed and diluted with ethanol to 3 mL final volume.
  • an aqueous buffered solution (10 mM citrate/150 mM NaCl, pH 4.5) of EPO mRNA was prepared from a 1 mg/mL stock.
  • the lipid solution was injected rapidly into the aqueous mRNA solution and shaken to yield a final suspension in 20% ethanol.
  • the resulting nanoparticle suspension was filtered, diafiltrated with lx PBS (pH 7.4), concentrated, and stored at 2-8°C.
  • Final concentration 1.35 mg/mL EPO mRNA (encapsulated).
  • This example illustrates exemplary methods for analyzing stability of modified mRNA and protein expression in various target tissues in vivo.
  • nucleoside mixture was applied to an Amicon spin column (30,000 MWCO) for efficient enzyme removal.
  • Amicon spin column 30,000 MWCO
  • the resulting nucleoside solution was analyzed via HPLC and quantified via peak area comparison with respective unmodified nucleoside.
  • 6078040vl Attorney Docket No.: 2006685-0457 at select time points (eg. 6 hr, 12 hr, 24 hr, 48 hr, 72 hr, etc.) and respective protein levels were monitored.
  • liver homogenates were analyzed for luciferase production via bio luminescence assays.
  • EPO and GLA mRNA studies mouse sera were obtained and analyzed for EPO and GLA protein, respectively, using ELISA-based methods. A comparison of protein production over time of unmodified versus 4'-thio NTP modified mRNA was made.
  • This example describes the protocol for analyzing exemplary protein production after administering either naked, modiefied, mRNA or mRNA-loaded nanoparticles and demonstrates mRNA stability and protein production for 4'-thio modified mRNA compared to unmodified mRNA.
  • liver and spleen of each mouse was harvested, apportioned into three parts, and stored in either 10% neutral buffered formalin or snap-frozen and stored at -80°C for analysis.
  • 6078040vl Attorney Docket No.: 2006685-0457 puncture or tail snip. Samples collected from non-treatment animals were used for baseline GLA levels for comparison to study animals.
  • EPO protein was prepared following procedures reported for human EPO ELISA kit (Quantikine IVD, R&D Systems, Catalog # Dep-00). Positive controls employed consisted of ultrapure and tissue culture grade recombinant human erythropoietin protein (R&D Systems, Catalog # 286-EP and 287-TC, respectively). Blood samples were taken at designated time points and processed as described above. Detection was monitored via absorption (450 nm) on a Molecular Device Flex Station instrument.
  • the Luciferase Assay Reagent was prepared by adding 10 mL of Luciferase Assay Buffer to Luciferase Assay Substrate and mixed via vortex. 20 uL of homogenate samples were loaded onto a 96-well plate followed by 20 uL of plate control to each sample. Separately, 120 uL of Luciferase Assay Reagent (prepared as described above) was loaded into each well of a 96-well flat bottomed plate. Each plate was then inserted into the appropriate chambers using a Molecular Device Flex Station instrument and the luminescence was measured in relative light units (RLU).
  • RLU relative light units
  • FFL mRNA was tested in HEK 293T cells.
  • Figure 2 represents the weighted relative fluorescence units (RLU) scores taken 4 hours, 8 hours, 32 hours, 56 hours and 80 hours after transfection.
  • RLU relative fluorescence units
  • FFL mRNA was tested in wild-type mice.
  • a 1.0 mg/kg dose of C12-200-loaded lipid nanoparticles was administered intravenously and animals were sacrificed and their livers were removed for analysis, as described above.
  • Figure 4 represents RLU/mg Total Protein scores taken six hours post-administration. Livers from mice treated with 25% 4'-thio uridine (25% 4'- S-U) and 100% 4'-thio uridine (100% 4'-S-U) had higher RLU/mg scores than the livers from mice treated with unmodified mRNA.
  • a provided mRNA comprising 4'-thio-modified nucleotide can be successfully synthesized, have increased stability, and can be used successfully to produce protein in cells.
  • 6078040vl Attorney Docket No.: 2006685-0457 borohydride (1.4 g, 0.036 mol, 1.5 equiv.) portion-wise at room temperature.
  • the reaction mixture was stirred for 1 h at room temperature and then concentrated under reduced pressure.
  • the residue was partitioned between ethyl acetate and IM aq. citric acid.
  • the organic layer was washed with IM aq. citric acid, brine, dried over magnesium sulphate, filtered and concentrated under reduced pressure to give 5-0-tert-butyldimethylsilyl-2,3-0-isopropylidene-L-lyxitol as a colourless oil which crystallised upon standing (6.3 g, 86%).
  • 6078040vl Attorney Docket No.: 2006685-0457 d][l,3]dioxole 5-oxide (2.0 g, 6.25 mmol) in dichloromethane (34 ml) and then triethylamine (3.5 ml, 25 mmol) was added. After stirring for 90 minutes at room temperature, the reaction was quenched with ice and then diluted with ethyl acetate. The layers were separated and the organic washed with saturated sodium bicarbonate solution (x 2) and then brine.
  • x 2 saturated sodium bicarbonate solution
  • nucleoside 5 '-triphosphates The synthesis of the nucleoside 5 '-triphosphates is shown above. Nucleoside A is reacted with phosphoramidite reagent in presence of imidazole.HCl / imidazole in
  • a cooled solution (ice-water bath) of trifluoroacetic anhydride (5 eq.) in acetonitrile (0.3 ml / mmol of trifluoroacetic anhydride) is added dropwise to a cooled suspension of C (1 eq.) in acetonitrile (4 ml / mmol of C), triethylamine (1 eq.) and N,N- dimethylaniline (4 eq.) under argon.
  • the reaction is then allowed to warm to room temperature, stirred at RT for 30 min and the volatiles are removed under reduced pressure.
  • the combined aqueous layers are directly loaded onto a column packed with DEAE Sepharose fast flow and eluted with a gradient of triethylammonium bicarbonate buffer from 0.01M to 0.5M.
  • the product-containing fractions are combined and freeze dried.
  • the resulting nucleoside triphosphate triethylamine salt is dissolved in deionised water and then subjected to a Dowex 50 W 8 ion exchange column.
  • the fractions that show UV activity are combined and the water is removed by freeze drying to give the nucleoside 5 '-triphosphate as its sodium salt.
  • dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
PCT/US2014/027422 2013-03-14 2014-03-14 RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS WO2014152513A1 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
MX2015011943A MX2015011943A (es) 2013-03-14 2014-03-14 Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados.
US14/776,506 US10266559B2 (en) 2013-03-14 2014-03-14 Ribonucleic acids with 4′-thio-modified nucleotides and related methods
CN201480010106.8A CN105026411A (zh) 2013-03-14 2014-03-14 含4’-硫代修饰的核苷酸的核糖核酸及相关方法
EP14721635.2A EP2970351B1 (en) 2013-03-14 2014-03-14 Ribonucleic acids with 4'-thio-modified nucleotides and related methods
ES14721635.2T ES2647832T3 (es) 2013-03-14 2014-03-14 Ácidos ribonucleicos con nucleótidos modificados con 4-tio y procedimientos relacionados
BR112015022507A BR112015022507A2 (pt) 2013-03-14 2014-03-14 ácidos ribonucleicos com nucleotídeos 4'-tio-modificados, composição compreendendo o mesmo e usos relacionados
JP2016502430A JP6567494B2 (ja) 2013-03-14 2014-03-14 ４’−チオ−修飾ヌクレオチドを有するリボ核酸及び関連方法
EP20169380.1A EP3750903A1 (en) 2013-03-14 2014-03-14 Ribonucleic acids with 4'-thio-modified nucleotides and related methods
CA2902884A CA2902884C (en) 2013-03-14 2014-03-14 Ribonucleic acids with 4'-thio-modified nucleotides and related methods
AU2014239562A AU2014239562B2 (en) 2013-03-14 2014-03-14 Ribonucleic acids with 4'-thio-modified nucleotides and related methods
SG11201507474QA SG11201507474QA (en) 2013-03-14 2014-03-14 RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
EA201591281A EA201591281A1 (ru) 2013-03-14 2014-03-14 Рибонуклеиновые кислоты с 4'-тиомодифицированными нуклеотидами и связанные с ними способы
EP17189627.7A EP3301102B1 (en) 2013-03-14 2014-03-14 Ribonucleic acids with 4'-thio-modified nucleotides and related methods
KR1020157021965A KR20150127582A (ko) 2013-03-14 2014-03-14 4''-티오 개질된 뉴클레오티드를 갖는 리보핵산 및 관련 방법
IL240465A IL240465A0 (he) 2013-03-14 2015-08-10 חומצות ריבונוקליאיות עם 4'–תיו–נוקליאוטידים שונים ושיטות קשורות
ZA2015/07605A ZA201507605B (en) 2013-03-14 2015-10-13 Ribonucleic acids with 4'-thio-modified nucleotides and related methods
HK16107939.1A HK1219955A1 (zh) 2013-03-14 2016-07-07 '- '-硫代修飾的核苷酸的核糖核酸及相關方法
AU2018203985A AU2018203985B2 (en) 2013-03-14 2018-06-05 RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
US16/282,106 US10822368B2 (en) 2013-03-14 2019-02-21 Ribonucleic acids with 4′-thio-modified nucleotides and related methods
US17/032,485 US11447520B2 (en) 2013-03-14 2020-09-25 Ribonucleic acids with 4′-thio-modified nucleotides and related methods
US17/818,858 US20230192753A1 (en) 2013-03-14 2022-08-10 Ribonucleic acids with 4'-thio-modified nucleotides and related methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785098P 2013-03-14 2013-03-14
US61/785,098 2013-03-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/776,506 A-371-Of-International US10266559B2 (en) 2013-03-14 2014-03-14 Ribonucleic acids with 4′-thio-modified nucleotides and related methods
US16/282,106 Continuation US10822368B2 (en) 2013-03-14 2019-02-21 Ribonucleic acids with 4′-thio-modified nucleotides and related methods

Publications (1)

Publication Number Publication Date
WO2014152513A1 true WO2014152513A1 (en) 2014-09-25

Family

ID=50639964

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/027422 WO2014152513A1 (en) 2013-03-14 2014-03-14 RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS

Country Status (16)

Country Link
US (4) US10266559B2 (he)
EP (3) EP3301102B1 (he)
JP (1) JP6567494B2 (he)
KR (1) KR20150127582A (he)
CN (1) CN105026411A (he)
AU (2) AU2014239562B2 (he)
BR (1) BR112015022507A2 (he)
CA (1) CA2902884C (he)
EA (1) EA201591281A1 (he)
ES (2) ES2647832T3 (he)
HK (1) HK1219955A1 (he)
IL (1) IL240465A0 (he)
MX (1) MX2015011943A (he)
SG (1) SG11201507474QA (he)
WO (1) WO2014152513A1 (he)
ZA (1) ZA201507605B (he)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9181321B2 (en) 2013-03-14 2015-11-10 Shire Human Genetic Therapies, Inc. CFTR mRNA compositions and related methods and uses
US9308281B2 (en) 2011-06-08 2016-04-12 Shire Human Genetic Therapies, Inc. MRNA therapy for Fabry disease
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
WO2017180917A2 (en) 2016-04-13 2017-10-19 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
WO2017201350A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
US9957499B2 (en) 2013-03-14 2018-05-01 Translate Bio, Inc. Methods for purification of messenger RNA
US10005779B2 (en) * 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2018157141A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
WO2018157133A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
JP2019513372A (ja) * 2016-04-08 2019-05-30 トランスレイト バイオ， インコーポレイテッド 多量体コード核酸及びその使用
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US10385106B2 (en) 2012-04-02 2019-08-20 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
US10406112B2 (en) 2015-12-17 2019-09-10 Modernatx, Inc. Polynucleotides encoding methylmalonyl-CoA mutase
WO2019232103A1 (en) * 2018-05-30 2019-12-05 Translate Bio, Inc. Messenger rna vaccines and uses thereof
US10507183B2 (en) 2011-06-08 2019-12-17 Translate Bio, Inc. Cleavable lipids
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
US10576166B2 (en) 2009-12-01 2020-03-03 Translate Bio, Inc. Liver specific delivery of messenger RNA
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
WO2020097509A1 (en) 2018-11-08 2020-05-14 Translate Bio, Inc. Methods and compositions for messenger rna purification
US10772975B2 (en) 2012-04-02 2020-09-15 Modernatx, Inc. Modified Polynucleotides for the production of biologics and proteins associated with human disease
US10898574B2 (en) 2011-03-31 2021-01-26 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US11027025B2 (en) 2013-07-11 2021-06-08 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
US11103596B2 (en) 2015-05-11 2021-08-31 Ucl Business Plc Fabry disease gene therapy
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
US11254936B2 (en) 2012-06-08 2022-02-22 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
US11377643B2 (en) 2017-05-31 2022-07-05 Ultragenyx Pharmaceutical Inc. Therapeutics for glycogen storage disease type III
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
US11801227B2 (en) 2016-05-18 2023-10-31 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2023239190A1 (ko) * 2022-06-10 2023-12-14 주식회사 피노바이오 4'-티오-5-아자-2'-데옥시사이티딘의 제조방법
US11859215B2 (en) 2017-11-22 2024-01-02 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7114485B2 (ja) 2016-05-18 2022-08-08 モデルナティエックス インコーポレイテッド ファブリー病の治療のためのα－ガラクトシダーゼＡをコードするポリヌクレオチド
US10961184B2 (en) 2017-03-07 2021-03-30 Translate Bio, Inc. Polyanionic delivery of nucleic acids
MA49393A (fr) 2017-06-12 2020-04-22 Translate Bio Inc Poly(phosphoesters) destinés à l'administration d'acides nucléiques
US10780183B2 (en) 2017-06-19 2020-09-22 Translate Bio, Inc. Messenger RNA therapy for the treatment of Friedreich's ataxia
US11975110B2 (en) 2018-02-02 2024-05-07 Translate Bio, Inc. Cationic polymers
US20210220449A1 (en) * 2018-05-15 2021-07-22 Translate Bio, Inc. Subcutaneous Delivery of Messenger RNA
CA3100218A1 (en) 2018-05-16 2019-11-21 Translate Bio, Inc. Ribose cationic lipids
JP7488193B2 (ja) 2018-05-24 2024-05-21 トランスレイト バイオ， インコーポレイテッド チオエステルカチオン性脂質
CA3100214A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Cationic lipids comprising a steroidal moiety
CN112533909A (zh) 2018-05-30 2021-03-19 川斯勒佰尔公司 维生素阳离子脂质
WO2019232097A1 (en) 2018-05-30 2019-12-05 Translate Bio, Inc. Phosphoester cationic lipids
KR20210056331A (ko) * 2018-07-23 2021-05-18 트랜슬레이트 바이오 인코포레이티드 전령 rna의 건조 분말 제형
EP3856757A4 (en) 2018-09-28 2022-06-29 Nutcracker Therapeutics, Inc. Tertiary amino lipidated cationic peptides for nucleic acid delivery
DK3864163T3 (da) 2018-10-09 2024-05-06 Univ British Columbia Sammensætninger og systemer omfattende transfektionskompetente vesikler fri for organiske opløsningsmidler og rengøringsmidler og fremgangsmåder forbundet dermed
AU2019377525A1 (en) 2018-11-09 2021-05-27 Translate Bio, Inc. Multi-PEG lipid compounds
US20220071905A1 (en) 2018-11-09 2022-03-10 Translate Bio, Inc. Peg lipidoid compounds
MX2021005482A (es) 2018-11-09 2021-09-08 Translate Bio Inc Lípidos de 2,5-dioxopiperazina con porciones éster, tioéster, disulfuro y anhidrido intercaladas.
WO2020106903A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
US20220177423A1 (en) 2019-04-18 2022-06-09 Translate Bio, Inc. Cystine cationic lipids
WO2020219427A1 (en) 2019-04-22 2020-10-29 Translate Bio, Inc. Thioester cationic lipids
EP3962902A1 (en) 2019-05-03 2022-03-09 Translate Bio, Inc. Di-thioester cationic lipids
WO2020243540A1 (en) 2019-05-31 2020-12-03 Translate Bio, Inc. Macrocyclic lipids
WO2020257611A1 (en) 2019-06-21 2020-12-24 Translate Bio, Inc. Cationic lipids comprising an hydroxy moiety
CN114401942B (zh) 2019-06-21 2024-01-26 川斯勒佰尔公司 三(羟甲基)甲基甘氨酸和柠檬酸脂质
CN111041025B (zh) 2019-12-17 2021-06-18 深圳市瑞吉生物科技有限公司 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法
WO2021202788A2 (en) * 2020-04-03 2021-10-07 Ionis Pharmaceuticals, Inc. Modified oligomeric compounds and uses thereof
US20230226219A1 (en) 2020-05-14 2023-07-20 Translate Bio, Inc. Peg lipidoid compounds
CN111744019B (zh) 2020-07-01 2023-08-04 深圳瑞吉生物科技有限公司 基于甘露糖的mRNA靶向递送系统及其应用
CN114736260A (zh) * 2022-03-29 2022-07-12 上海吉量医药工程有限公司 一种三磷酸核苷酸盐的制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2011006810A2 (de) 2009-07-13 2011-01-20 Siemens Aktiengesellschaft Ringförmiger rotor für eine elektrische maschine
WO2011068810A1 (en) 2009-12-01 2011-06-09 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012170889A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc. Cleavable lipids
WO2012170930A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc Lipid nanoparticle compositions and methods for mrna delivery

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
WO2005027962A1 (en) 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
WO2008103276A2 (en) * 2007-02-16 2008-08-28 Merck & Co., Inc. Compositions and methods for potentiated activity of biologicaly active molecules
HUE057725T2 (hu) 2011-10-03 2022-06-28 Modernatx Inc Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
EP3052479A4 (en) 2013-10-02 2017-10-25 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
EP3053585A1 (en) 2013-12-13 2016-08-10 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2011006810A2 (de) 2009-07-13 2011-01-20 Siemens Aktiengesellschaft Ringförmiger rotor für eine elektrische maschine
WO2011068810A1 (en) 2009-12-01 2011-06-09 Shire Human Genetic Therapies Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2012170889A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc. Cleavable lipids
WO2012170930A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc Lipid nanoparticle compositions and methods for mrna delivery

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
A HUTTENHOFER AND H.F. NOLLER: "Footprinting mRNA-ribosome complexes with chemical probes", THE EMBO JOURNAL, vol. 13, no. 16, 1 January 1994 (1994-01-01), pages 3892 - 3901, XP055131438 *
B. R. ANDERSON ET AL: "Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L", NUCLEIC ACIDS RESEARCH, vol. 39, no. 21, 1 November 2011 (2011-11-01), pages 9329 - 9338, XP055126203, ISSN: 0305-1048, DOI: 10.1093/nar/gkr586 *
BOGACHEV, V.S.: "Synthesis of deoxynucleoside 5'-triphosphates using trifluoroacetic anhydride as activation reagent", RUSS. J. BIOORG. CHEM., vol. 22, 1996, pages 599 - 604
DANDE ET AL., J. MED. CHEM., vol. 49, 2006, pages 1624 - 1634
DANDE PRASAD ET AL: "Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 49, no. 5, 9 March 2006 (2006-03-09), pages 1624 - 1634, XP002611368, ISSN: 0022-2623, [retrieved on 20060208], DOI: 10.1021/JM050822C *
DEBUS, H. ET AL., J. CONTROL REL., vol. 148, 2010, pages 334 - 343
DEMESHKINA N ET AL: "Interactions of the ribosome with mRNA and tRNA", CURRENT OPINION IN STRUCTURAL BIOLOGY, ELSEVIER LTD, GB, vol. 20, no. 3, 1 June 2010 (2010-06-01), pages 325 - 332, XP027067342, ISSN: 0959-440X, [retrieved on 20100412], DOI: 10.1016/J.SBI.2010.03.002 *
DRUMMOND ET AL., PHARMACOL. REV., vol. 51, 1999, pages 691 - 743
FECHTER, P.; BROWNLEE, G.G.: "Recognition of mRNA cap structures by viral and cellular proteins", J. GEN. VIROLOGY, vol. 86, 2005, pages 1239 - 1249, XP002516933, DOI: doi:10.1099/VIR.0.80755-0
FECHTER; BROWNLEE, J. GEN. VIROLOGY, vol. 86, 2005, pages 1239 - 1249
HEYES ET AL., J. CONTR. REL., vol. 107, 2005, pages 276 - 287
HEYES, J.; PALMER, L.; BREMNER, K.; MACLACHLAN, 1: "Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids", J. CONTR. REL., vol. 107, 2005, pages 276 - 287, XP008157522, DOI: doi:10.1016/j.jconrel.2005.06.014
HOSHIKA ET AL., NUC. AC. RES., vol. 32, 2004, pages 3815 - 3825
HUM. GENE THER., vol. 19, no. 9, 2008, pages 887 - 95
JONES G D ET AL: "DUPLEX- AND TRIPLEX-FORMING PROPERTIES OF 4'-THIO-MODIFIED OLIGODEOXYNUCLEOTIDES", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 7, no. 10, 20 May 1997 (1997-05-20), pages 1275 - 1278, XP004136316, ISSN: 0960-894X, DOI: 10.1016/S0960-894X(97)00208-4 *
K. KARIKO, MOLECULAR THERAPY, vol. 16, no. 11, 2008, pages 1833 - 1840
KARIKÓ KATALIN ET AL: "Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 16, no. 11, 1 November 2008 (2008-11-01), pages 1833 - 1840, XP002598556, ISSN: 1525-0024, [retrieved on 20080916], DOI: 10.1038/MT.2008.200 *
KATO ET AL., NUC. AC. RES., vol. 33, 2005, pages 2942 - 2951
LASIC ET AL., TRENDS BIOTECHNOL., vol. 16, 1998, pages 307 - 321
LOVE ET AL., PROC. NAT'L. ACAD. SCI., vol. 107, 2010, pages 1864 - 1869
LOVE, K.T. ET AL.: "Lipid-like materials for low-dose in vivo gene silencing", PNAS, vol. 107, 2010, pages 1864 - 1869, XP055077922, DOI: doi:10.1073/pnas.0910603106
M. KORMANN ET AL., NATURE BIOTECH., vol. 29, 2011, pages 154 - 159
M. TAKAHASHI, M. ET AL., NUC. AC. RES., vol. 37, 2009, pages 1353 - 1362
MICHAEL S D KORMANN ET AL: "Expression of therapeutic proteins after delivery of chemically modified mRNA in mice", NATURE BIOTECHNOLOGY, vol. 29, no. 2, 1 February 2011 (2011-02-01), pages 154 - 157, XP055040839, ISSN: 1087-0156, DOI: 10.1038/nbt.1733 *
MINAKAWA ET AL., BIOORG. MED. CHEM., vol. 16, 2008, pages 9450 - 9456
S. HOSHIKA ET AL., NUC. AC. RES. SUPP., vol. 3, 2003, pages 209 - 210
SEMPLE ET AL., NATURE BIOTECH., vol. 28, 2010, pages 172 - 176
SEMPLE, S.C. ET AL.: "Rational Design of Cationic Lipids for siRNA Delivery", NATURE BIOTECH., vol. 28, 2010, pages 172 - 176, XP002633693, DOI: doi:10.1038/NBT.1602
YAMAMOTO, A. ET AL., EUR. J. PHARM., vol. 71, 2009, pages 484 - 489

Cited By (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576166B2 (en) 2009-12-01 2020-03-03 Translate Bio, Inc. Liver specific delivery of messenger RNA
US11911474B2 (en) 2011-03-31 2024-02-27 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US10898574B2 (en) 2011-03-31 2021-01-26 Modernatx, Inc. Delivery and formulation of engineered nucleic acids
US11185595B2 (en) 2011-06-08 2021-11-30 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11951179B2 (en) 2011-06-08 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US11338044B2 (en) 2011-06-08 2022-05-24 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11951181B2 (en) 2011-06-08 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US9597413B2 (en) 2011-06-08 2017-03-21 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mRNA
US9308281B2 (en) 2011-06-08 2016-04-12 Shire Human Genetic Therapies, Inc. MRNA therapy for Fabry disease
US11951180B2 (en) 2011-06-08 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US10888626B2 (en) 2011-06-08 2021-01-12 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11052159B2 (en) 2011-06-08 2021-07-06 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11730825B2 (en) 2011-06-08 2023-08-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10507183B2 (en) 2011-06-08 2019-12-17 Translate Bio, Inc. Cleavable lipids
US10507249B2 (en) 2011-06-08 2019-12-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11234936B2 (en) 2011-06-08 2022-02-01 Translate Bio, Inc. Cleavable lipids
US11547764B2 (en) 2011-06-08 2023-01-10 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US10413618B2 (en) 2011-06-08 2019-09-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10238754B2 (en) 2011-06-08 2019-03-26 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US11291734B2 (en) 2011-06-08 2022-04-05 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10350303B1 (en) 2011-06-08 2019-07-16 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10702478B2 (en) 2011-06-08 2020-07-07 Translate Bio, Inc. Cleavable lipids
US10385106B2 (en) 2012-04-02 2019-08-20 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US10703789B2 (en) 2012-04-02 2020-07-07 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US10577403B2 (en) 2012-04-02 2020-03-03 Modernatx, Inc. Modified polynucleotides for the production of secreted proteins
US10772975B2 (en) 2012-04-02 2020-09-15 Modernatx, Inc. Modified Polynucleotides for the production of biologics and proteins associated with human disease
US11254936B2 (en) 2012-06-08 2022-02-22 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
US10420791B2 (en) 2013-03-14 2019-09-24 Translate Bio, Inc. CFTR MRNA compositions and related methods and uses
US9181321B2 (en) 2013-03-14 2015-11-10 Shire Human Genetic Therapies, Inc. CFTR mRNA compositions and related methods and uses
US11510937B2 (en) 2013-03-14 2022-11-29 Translate Bio, Inc. CFTR MRNA compositions and related methods and uses
US11692189B2 (en) 2013-03-14 2023-07-04 Translate Bio, Inc. Methods for purification of messenger RNA
US9713626B2 (en) 2013-03-14 2017-07-25 Rana Therapeutics, Inc. CFTR mRNA compositions and related methods and uses
US10876104B2 (en) 2013-03-14 2020-12-29 Translate Bio, Inc. Methods for purification of messenger RNA
US11820977B2 (en) 2013-03-14 2023-11-21 Translate Bio, Inc. Methods for purification of messenger RNA
US9957499B2 (en) 2013-03-14 2018-05-01 Translate Bio, Inc. Methods for purification of messenger RNA
US10138507B2 (en) 2013-03-15 2018-11-27 Modernatx, Inc. Manufacturing methods for production of RNA transcripts
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
US11377470B2 (en) 2013-03-15 2022-07-05 Modernatx, Inc. Ribonucleic acid purification
US10858647B2 (en) 2013-03-15 2020-12-08 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
US11845772B2 (en) 2013-03-15 2023-12-19 Modernatx, Inc. Ribonucleic acid purification
US10005779B2 (en) * 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
US11027025B2 (en) 2013-07-11 2021-06-08 Modernatx, Inc. Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
US11377642B2 (en) 2013-10-22 2022-07-05 Translate Bio, Inc. mRNA therapy for phenylketonuria
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
US10208295B2 (en) 2013-10-22 2019-02-19 Translate Bio, Inc. MRNA therapy for phenylketonuria
US11059841B2 (en) 2014-04-25 2021-07-13 Translate Bio, Inc. Methods for purification of messenger RNA
US10155785B2 (en) 2014-04-25 2018-12-18 Translate Bio, Inc. Methods for purification of messenger RNA
US11884692B2 (en) 2014-04-25 2024-01-30 Translate Bio, Inc. Methods for purification of messenger RNA
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
US10286086B2 (en) 2014-06-19 2019-05-14 Modernatx, Inc. Alternative nucleic acid molecules and uses thereof
US10407683B2 (en) 2014-07-16 2019-09-10 Modernatx, Inc. Circular polynucleotides
US11103596B2 (en) 2015-05-11 2021-08-31 Ucl Business Plc Fabry disease gene therapy
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
US10426738B2 (en) 2015-12-17 2019-10-01 Modernatx, Inc. Polynucleotides encoding methylmalonyl-CoA mutase
US10406112B2 (en) 2015-12-17 2019-09-10 Modernatx, Inc. Polynucleotides encoding methylmalonyl-CoA mutase
US11504337B2 (en) 2015-12-17 2022-11-22 Modernatx, Inc. Polynucleotides encoding methylmalonyl-CoA mutase
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
JP2019513372A (ja) * 2016-04-08 2019-05-30 トランスレイト バイオ， インコーポレイテッド 多量体コード核酸及びその使用
US11124804B2 (en) 2016-04-08 2021-09-21 Translate Bio, Inc. Multimeric coding nucleic acid and uses thereof
JP7150608B2 (ja) 2016-04-08 2022-10-11 トランスレイト バイオ， インコーポレイテッド 多量体コード核酸及びその使用
JP7150608B6 (ja) 2016-04-08 2022-11-11 トランスレイト バイオ， インコーポレイテッド 多量体コード核酸及びその使用
WO2017180917A2 (en) 2016-04-13 2017-10-19 Modernatx, Inc. Lipid compositions and their uses for intratumoral polynucleotide delivery
US11801227B2 (en) 2016-05-18 2023-10-31 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
WO2017201350A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
WO2018157133A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
WO2018157141A1 (en) 2017-02-27 2018-08-30 Translate Bio, Inc. Methods for purification of messenger rna
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
US11377643B2 (en) 2017-05-31 2022-07-05 Ultragenyx Pharmaceutical Inc. Therapeutics for glycogen storage disease type III
WO2018231990A2 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Polynucleotides encoding methylmalonyl-coa mutase
US11859215B2 (en) 2017-11-22 2024-01-02 Modernatx, Inc. Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
US11939601B2 (en) 2017-11-22 2024-03-26 Modernatx, Inc. Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria
WO2019232103A1 (en) * 2018-05-30 2019-12-05 Translate Bio, Inc. Messenger rna vaccines and uses thereof
WO2020041793A1 (en) 2018-08-24 2020-02-27 Translate Bio, Inc. Methods for purification of messenger rna
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
WO2020097509A1 (en) 2018-11-08 2020-05-14 Translate Bio, Inc. Methods and compositions for messenger rna purification
WO2023239190A1 (ko) * 2022-06-10 2023-12-14 주식회사 피노바이오 4'-티오-5-아자-2'-데옥시사이티딘의 제조방법

Also Published As

Publication number Publication date
EP3301102B1 (en) 2020-04-15
ES2797974T3 (es) 2020-12-04
BR112015022507A2 (pt) 2017-10-24
US11447520B2 (en) 2022-09-20
JP6567494B2 (ja) 2019-08-28
EP3301102A1 (en) 2018-04-04
EP2970351A1 (en) 2016-01-20
US20230192753A1 (en) 2023-06-22
SG11201507474QA (en) 2015-10-29
EP2970351B1 (en) 2017-09-13
CA2902884A1 (en) 2014-09-25
ES2647832T3 (es) 2017-12-26
US20160031928A1 (en) 2016-02-04
AU2014239562A1 (en) 2015-08-27
AU2018203985A1 (en) 2018-06-21
AU2018203985B2 (en) 2019-09-19
ZA201507605B (en) 2017-01-25
AU2014239562B2 (en) 2018-07-05
US20210009629A1 (en) 2021-01-14
EP3750903A1 (en) 2020-12-16
CA2902884C (en) 2021-05-25
HK1219955A1 (zh) 2017-04-21
JP2016513470A (ja) 2016-05-16
IL240465A0 (he) 2015-09-24
US10822368B2 (en) 2020-11-03
MX2015011943A (es) 2015-12-01
KR20150127582A (ko) 2015-11-17
US20190263850A1 (en) 2019-08-29
CN105026411A (zh) 2015-11-04
EA201591281A1 (ru) 2016-02-29
US10266559B2 (en) 2019-04-23

Similar Documents

Publication Publication Date Title
US11447520B2 (en) Ribonucleic acids with 4′-thio-modified nucleotides and related methods
CN112437767B (zh) 硫酯阳离子脂质
WO2019232095A1 (en) Vitamin cationic lipids
JP7448488B2 (ja) メッセンジャーｒｎａの皮下送達
WO2019232097A1 (en) Phosphoester cationic lipids
JP2021525744A (ja) ステロイド性部分を含むカチオン性脂質
JP2022173314A (ja) メッセンジャーｒｎａの皮下送達
WO2020227085A1 (en) Di-thioester cationic lipids
KR20170021281A (ko) 핵산의 전달용 입체화학적으로 풍부한 조성물
WO2020214946A1 (en) Cystine cationic lipids
EP3883917A1 (en) Cationic lipid compounds and compositions thereof for use in the delivery of messenger rna
WO2020219427A1 (en) Thioester cationic lipids
EP3976593A1 (en) Macrocyclic lipids

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480010106.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14721635

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 201591281

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 240465

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 20157021965

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016502430

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014239562

Country of ref document: AU

Date of ref document: 20140314

Kind code of ref document: A

Ref document number: 2902884

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2014721635

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014721635

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/011943

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14776506

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015022507

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112015022507

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150911